Systematic Assessment of Tumor Purity and Its Clinical Implications | Zendy

Syed Haider | Zendy; Svitlana Tyekucheva | Zendy; Davide Prandi | Zendy; Natalie S. Fox | Zendy; Jaeil Ahn | Zendy; Andrew Wei Xu | Zendy; Angeliki Pantazi | Zendy; Peter J. Park | Zendy; Peter W. Laird | Zendy; Chris Sander | Zendy; Wenyi Wang | Zendy; Francesca Demichelis | Zendy; Massimo Loda | Zendy; Paul C. Boutros | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Systematic Assessment of Tumor Purity and Its Clinical Implications

Author(s) -

Syed Haider,

Svitlana Tyekucheva,

Davide Prandi,

Natalie S. Fox,

Jaeil Ahn,

Andrew Wei Xu,

Angeliki Pantazi,

Peter J. Park,

Peter W. Laird,

Chris Sander,

Wenyi Wang,

Francesca Demichelis,

Massimo Loda,

Paul C. Boutros

Publication year - 2020

Publication title -

jco precision oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.405

H-Index - 22

ISSN - 2473-4284

DOI - 10.1200/po.20.00016

Subject(s) - prostate cancer , concordance , cancer , computational biology , biology , transcriptome , bioinformatics , oncology , medicine , genetics , gene expression , gene

The tumor microenvironment is complex, comprising heterogeneous cellular populations. As molecular profiles are frequently generated using bulk tissue sections, they represent an admixture of multiple cell types (including immune, stromal, and cancer cells) interacting with each other. Therefore, these molecular profiles are confounded by signals emanating from many cell types. Accurate assessment of residual cancer cell fraction is crucial for parameterization and interpretation of genomic analyses, as well as for accurately interpreting the clinical properties of the tumor.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research